Supplementary Material
Table 1. Age, smoking status, and semen parameters of subjects in the test set.
Control
Asthenozoosper
Oligoasthenozoo Casesa
(n=194)
mia (n=115)
spermia (n=90)
(n=205)
b
Age(yrs)
34.5 ± 5.1
34.2 ± 5.7
35.1 ± 5.3
34.6 ± 5.5
Nonsmoker (%)c
42.3
52.3
44.0
49.2
Heavy smoker(%)c
19.0
7.5
25.3
14.9
Smoking indexc
78
58
93
72
Concentration(106/mL) b 91.12 ± 50.99 46.65 ± 30.04
11.79 ± 5.19
31.35 ± 28.58
Progressive Motility (%)b 67 ± 8
20 ± 7
18 ± 7
19 ± 7
Immotility (%)b
25 ± 7
76 ± 8
78 ± 7
77 ± 7
Vitality (%)b
90 ± 4
68 ± 14
67 ± 16
68 ± 15
a: All asthenozoospermic and oligoasthenozoospermic patients.
b: Data was presented as mean value ± standard derivation.
c: Information of smoking dose and years smoked was acquired from patients. Smoking index was
calculated by multiplying smoking dose (cigarettes per day) and duration (years smoked). Patients
with smoking index ≥200 are heavy smokers.
1
Table 2. Age, smoking status, and semen parameters of subjects in the validation
set.
Control
Asthenozoosper
Oligoasthenozoo Casesa
(n=101)
mia (n=81)
spermia (n=50)
(n=131)
b
Age(yrs)
33.3 ± 4.3
37.3 ± 7.1
34.0 ± 5.8
36.0 ± 6.9
Nonsmoker (%)c
25.7
21.0
36.0
26.7
Heavy smoker(%)c
12.9
13.6
8.0
11.5
Smoking indexc
88
114
55
91
Concentration(106/mL) b 78.16 ± 49.24 56.45 ± 44.74
11.39 ± 5.04
39.25 ± 41.55
Progressive Motility (%)b 64 ± 7
24 ± 10
19 ± 7
22 ± 107
Immotility (%)b
29 ± 7
69 ± 12
74 ± 10
71 ± 12
Vitality (%)b
89 ± 5
73 ± 16
70 ± 17
72 ± 17
a: All asthenozoospermic and oligoasthenozoospermic patients.
b: Data was presented as mean value ± standard derivation.
c: Information of smoking dose and years smoked was acquired from patients. Smoking index was
calculated by multiplying smoking dose (cigarettes per day) and duration (years smoked). Patients
with smoking index ≥200 are heavy smokers.
2
Table 3. Genotypes and allele frequencies of the Nrf2 promoters of subjects in the
test set.
Genotypea
-617
G/G
T/T
G/T
G
T
Control
(n=194)b
109(56.19%)
12(6.19%)
73(37.63%)
291(75.00%)
97(25.00%)
Asthenozoospermia
(n=115)b
63(54.78%)
9(7.83%)
43(37.39%)
169(73.48%)
61(26.52%)
Oligoasthenozoosper
mia (n=90) b
43(47.78%)
13(14.44%)
34(37.78%)
120(66.67%)
60(33.33%)
Cases
(n=205) b,c
106(51.71%)
22(10.73%)
77(37.56%)
289(70.49%)
121(29.51%)
-651
C/C
T/T
C/T
C
T
180(92.78%)
0(0.00%)
14(7.22%)
374(96.39%)
14(3.61%)
106(92.17%)
0(0.00%)
9(7.83%)
221(96.09%)
9(3.91%)
79(87.78%)
1(1.11%)
10(11.11%)
168(93.33%)
12(6.67%)
185(90.24%)
1(0.49%)
19(9.27%)
389(94.88%)
21(5.12%)
-653
T/T
C/C
T/C
T
C
43(22.16%)
61(31.44%)
90(46.39%)
176(45.36%)
212(54.64%)
27(23.48%)
32(27.83%)
56(48.70%)
110(47.83%)
120(52.17%)
31(34.44%)
16(17.78%)
43(47.78%)
105(58.33%)
75(41.67%)
58(28.29%)
48(23.41%)
99(48.29%)
215(52.44%)
195(47.56%)
a:
-617: Nrf2 SNP rs6721961; -651:Nrf2 SNP rs6706649; -653: Nrf2 SNP rs35652124.
Data was presented as case number (% of total number).
c: All asthenozoospermic and oligoasthenozoospermic patients.
b:
3
Table 4. Genotypes and allele frequencies of the Nrf2 promoters of subjects in the
validation set.
Genotypea
-617
G/G
T/T
G/T
G
T
Control
(n=101)b
59(58.42%)
5(4.95%)
37(36.63%)
155(76.73%)
47(23.27%)
Asthenozoospermia
(n=81)b
42(51.85%)
7(8.64%)
32(39.51%)
116(71.60%)
46(28.40%)
Oligoasthenozoosper
mia (n=50) b
17(34.00%)
6(12.00%)
27(54.00%)
61(61.00%)
39(39.00%)
Cases
(n=131) b,c
59(45.04%)
13(9.92%)
59(45.04%)
177(67.56%)
85(32.44%)
-651
C/C
T/T
C/T
C
T
87(86.14%)
0(0.00%)
14(13.86%)
188(93.07%)
14(6.93%)
78(96.30%)
0(0.00%)
3(3.70%)
159(98.15%)
3(1.85%)
47(94.00%)
0(0.00%)
3(6.00%)
97(97.00%)
3 (3.00%)
125(95.42%)
0(0.00%)
6(4.58%)
256(97.71%)
6(2.29%)
-653
T/T
C/C
T/C
T
C
15(14.85%)
22(21.78%)
64(63.37%)
94(46.53%)
108(53.47%)
18(22.22%)
22(27.16%)
41(50.62%)
77(47.53%)
85(52.47%)
16(32.00%)
8(16.00%)
26(52.00%)
58(58.00%)
42(42.00%)
34(25.95%)
30(22.90%)
67(51.15%)
135(51.53%)
127(48.47%)
a:
-617: Nrf2 SNP rs6721961; -651:Nrf2 SNP rs6706649; -653: Nrf2 SNP rs35652124.
Data was presented as case number (% of total number).
c: All asthenozoospermic and oligoasthenozoospermic patients.
b:
4
Table 5. Haplotypes of the Nrf2 promoters of subjects in the test set.
Haplotypea
Control (n=194)b
GCT
9(4.64%)
60(30.93%)
12(6.19%)
0(0.00%)
113(58.25%)
GCC
TCT
GTT
Hetero
a
Asthenozoospermia
(n=115)b
a
Oligoasthenozoosper
mia (n=90)b
a
3(2.61%)
32(27.83%)
9(7.83%)
0(0.00%)
71(61.74%)
5(5.56%)
16(17.78%)
12(13.33%)
1(1.11%)
56(62.22%)
a
Cases (n=205)b,c
a
8(3.90%)
48(23.41%)
21(10.24%)
1(0.49%)
127(61.95%)
: Three alleles at position -617 (rs6721961), -651 (rs6706649) and -653 (rs35652124) of the Nrf2
promoter.
b
: Data was presented as case number (% of total number).
c
: All asthenozoospermic and oligoasthenozoospermic patients.
5
Table 6. Haplotypes of the Nrf2 promoters of subjects in the validation set.
Haplotypea
Control (n=101)b
GCT
2(1.98%)
21(20.79%)
5(4.95%)
0(0.00%)
73(72.28%)
GCC
TCT
GTT
Hetero
a
Asthenozoospermia
(n=81)b
a
Oligoasthenozoospermi
a (n=50)b
a
3(3.70%)
22(27.16%)
7(8.64%)
0(0.00%)
49(60.49%)
0(0.00%)
8(16.00%)
6(12.00%)
0(0.00%)
36(72.00%)
a
Cases(n=131)b,c
a
3(2.29%)
30(22.90%)
13(9.92%)
0(0.00%)
85(64.89)
: Three alleles at position -617 (rs6721961), -651 (rs6706649) and -653 (rs35652124) of Nrf2
promoter.
b
: Data was presented as case number (% of total number).
c
: All asthenozoospermic and oligoasthenozoospermic patients.
6
Table 7. Seminal SOD activities analyzed by individual genotypes in the test set.
Genotypea
Group
SOD activity (U/mg)b
All
Control
Asthenozoospermia
Oligoasthenozoospermia
3.07 ± 1.11
2.68 ± 1.13
2.43 ± 0.90
617TT
Control
Asthenozoospermia
Oligoasthenozoospermia
2.85 ± 1.38
2.71 ± 1.46
2.61 ± 1.24
617GG
Control
Asthenozoospermia
Oligoasthenozoospermia
3.24 ± 1.10
2.75 ± 1.20
2.30 ± 0.74
653TT
Control
Asthenozoospermia
Oligoasthenozoospermia
2.97 ± 1.17
2.56 ± 1.14
2.35 ± 0.97
653CC
Control
3.14 ± 0.91
Asthenozoospermia
2.60 ± 0.79
Oligoasthenozoospermia
2.35 ± 0.85
a: All: all controls and patients; 617TT: controls or patients with the Nrf2 -617TT genotype; 617GG:
controls or patients with the Nrf2 -617GG genotype; 653TT: controls or patients with the Nrf2 -653 TT
genotype; 653CC: controls or patients with the Nrf2 -653CC genotype.
b: Data was presented as mean value ± standard derivation.
7
Table 8. Seminal SOD activities analyzed by individual genotypes in the validation
set.
Genotypea
Group
SOD activity (U/mg)b
All
Control
Asthenozoospermia
Oligoasthenozoospermia
2.84 ± 1.03
2.52 ± 1.09
2.46 ± 0.95
617TT
Control
Asthenozoospermia
Oligoasthenozoospermia
2.24 ± 0.60
2.39 ± 0.89
2.22 ± 0.50
617GG
Control
Asthenozoospermia
Oligoasthenozoospermia
3.08 ± 1.54
2.37 ± 1.08
2.35 ± 0.92
653TT
Control
Asthenozoospermia
Oligoasthenozoospermia
2.60 ± 0.76
2.40 ± 0.75
2.30 ± 0.58
653CC
Control
2.85 ± 1.23
Asthenozoospermia
2.44 ± 1.07
Oligoasthenozoospermia
2.34 ± 0.97
a: All: all controls and patients; 617TT: controls or patients with the Nrf2 -617TT genotype; 617GG:
controls or patients with the Nrf2 -617GG genotype; 653TT: controls or patients with the Nrf2 -653
TT genotype; 653CC: controls or patients with the Nrf2 -653CC genotype.
b
: Data was presented as mean value ± standard derivation.
8